Volume 23, Issue 2 (Summer 2026)
bloodj 2026, 23(2): 173-190 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Farzaneh F, Sadeghi M, Mousavi Hosseini K, Vosough M, Salehi M. Platelet‑Derived Extracellular Vesicles: A New Generation of Drug Carriers. bloodj 2026; 23 (2) :173-190
URL: http://bloodjournal.ir/article-1-1639-en.html
URL: http://bloodjournal.ir/article-1-1639-en.html
Abstract: (220 Views)
A B S T R A C T
Background and Objectives
Platelet-derived extracellular vesicles (PEVs) are lipid-bilayer membrane-enclosed particles released by platelets into the extracellular space. They carry a diverse array of bioactive molecules, including proteins, metabolites, coagulation factors, cytokines, lipids, and miRNAs. Through the transfer of these bioactive cargos to recipient cells, PEVs participate in various physiological and pathological processes, including hemostasis, inflammation, regulation of immune responses, and tissue repair. Their lack of nuclear DNA, intrinsic biological activity, and potential for relatively large-scale, and cost-effective isolation have attracted increasing attention to PEVs as promising carriers for drug-delivery applications.
Materials and Methods
In this narrative review, relevant studies addressing the biology, molecular composition, functional characteristics, isolation approaches, drug-loading strategies, and drug-delivery applications of PEVs were comprehensively examined. The literature search included articles indexed in reputable databases, including PubMed and Google Scholar.
Results
PEVs have demonstrated potential for delivering a broad range of therapeutic cargos, including chemotherapeutic agents, miRNAs, antivirals, and anti-inflammatory agents to target cells. The delivery of drugs using PEVs may improve drug stability, enhance cellular uptake, and increase therapeutic efficacy while reducing undesirable side effects. However, the lack of standardized isolation methods and drug-loading procedures remains an important obstacle. Moreover, the stability of PEVs during storage should be further investigated.
Conclusions
Despite the considerable potential of PEVs as drug-delivery carriers, their successful clinical translation will require standardization and optimization of isolation methods and drug-loading application. Further studies are needed to comprehensively evaluate their safety profile, particularly their procoagulant activity and potential risk of thrombosis, as well as possible immunogenicity following repeated administration. Additional investigations are also required to determine optimal storage conditions that preserve vesicular structural integrity and biological activity during long-term storage.
Background and Objectives
Platelet-derived extracellular vesicles (PEVs) are lipid-bilayer membrane-enclosed particles released by platelets into the extracellular space. They carry a diverse array of bioactive molecules, including proteins, metabolites, coagulation factors, cytokines, lipids, and miRNAs. Through the transfer of these bioactive cargos to recipient cells, PEVs participate in various physiological and pathological processes, including hemostasis, inflammation, regulation of immune responses, and tissue repair. Their lack of nuclear DNA, intrinsic biological activity, and potential for relatively large-scale, and cost-effective isolation have attracted increasing attention to PEVs as promising carriers for drug-delivery applications.
Materials and Methods
In this narrative review, relevant studies addressing the biology, molecular composition, functional characteristics, isolation approaches, drug-loading strategies, and drug-delivery applications of PEVs were comprehensively examined. The literature search included articles indexed in reputable databases, including PubMed and Google Scholar.
Results
PEVs have demonstrated potential for delivering a broad range of therapeutic cargos, including chemotherapeutic agents, miRNAs, antivirals, and anti-inflammatory agents to target cells. The delivery of drugs using PEVs may improve drug stability, enhance cellular uptake, and increase therapeutic efficacy while reducing undesirable side effects. However, the lack of standardized isolation methods and drug-loading procedures remains an important obstacle. Moreover, the stability of PEVs during storage should be further investigated.
Conclusions
Despite the considerable potential of PEVs as drug-delivery carriers, their successful clinical translation will require standardization and optimization of isolation methods and drug-loading application. Further studies are needed to comprehensively evaluate their safety profile, particularly their procoagulant activity and potential risk of thrombosis, as well as possible immunogenicity following repeated administration. Additional investigations are also required to determine optimal storage conditions that preserve vesicular structural integrity and biological activity during long-term storage.
Type of Study: Review Article |
Subject:
Biotechnology
References
1. Bakrey H, Abdu A, Shivgotra R, Soni B, Sharma M, Bakrey A, et al. Innovative Strategies and Advances in Drug Delivery Systems to Address Poor Solubility: A Comprehensive Review. Curr Drug Targets. 2025 ; 26(13):879-902. [DOI:10.2174/0113894501375776250713110838] [PMID]
2. Chaudhary A, Shambhakar S. Nanotechnology in Drug Delivery: Overcoming Poor Solubility Challenges through Nanoformulations. CN. 2024; 14(3): 200-11. [DOI:10.2174/0124681873276732231207051324]
3. Islam S, Ahmed MMS, Islam MA, Hossain N, Chowdhury MA. Advances in nanoparticles in targeted drug delivery-A review. Results in Surfaces and Interfaces. 2025; 19: 100529. [DOI:10.1016/j.rsurfi.2025.100529]
4. Abels ER, Breakefield XO. Introduction to Extracellular Vesicles: Biogenesis, RNA Cargo Selection, Content, Release, and Uptake. Cell Mol Neurobiol. 2016; 36(3): 301-12. [DOI:10.1007/s10571-016-0366-z] [PMID]
5. Colombo M, Raposo G, Théry C. Biogenesis, secretion, and intercellular interactions of exosomes and other extracellular vesicles. Annu Rev Cell Dev Biol. 2014; 30: 255-89. [DOI:10.1146/annurev-cellbio-101512-122326] [PMID] [PMCID]
6. Théry C, Zitvogel L, Amigorena S. Exosomes: composition, biogenesis and function. Nat Rev Immunol. 2002; 2(8): 569-79. [DOI:10.1038/nri855] [PMID]
7. Lötvall J, Hill AF, Hochberg F, Buzás EI, Di Vizio D, Gardiner C, et al. Minimal experimental requirements for definition of extracellular vesicles and their functions: a position statement from the International Society for Extracellular Vesicles. J Extracell Vesicles. 2014; 3: 26913. [DOI:10.3402/jev.v3.26913] [PMID]
8. Théry C, Ostrowski M, Segura E. Membrane vesicles as conveyors of immune responses. Nat Rev Immunol. 2009; 9(8): 581-93. [DOI:10.1038/nri2567] [PMID]
9. Salehi M, Vafadar A, Khatami SH, Taheri-Anganeh M, Vakili O, Savardashtaki A, et al. Gastrointestinal cancer drug resistance: the role of exosomal miRNAs. Mol Biol Rep. 2022; 49(3): 2421-32. [DOI:10.1007/s11033-021-07007-3] [PMID]
10. Ghaffari Gabaran S, Hassani S, Mahmoodi M, Salehi M, Rezaie J. Bacterial extracellular vesicles in colorectal cancer: mechanisms, biomarker potential, and therapeutic engineering. Cell Commun Signal . 2026; 24(1): 99. [DOI:10.1186/s12964-025-02634-w] [PMID] [PMCID]
11. Salehi M, Sharifi M. Exosomal miRNAs as novel cancer biomarkers: Challenges and opportunities. J Cell Physiol. 2018; 233(9): 6370-80. [DOI:10.1002/jcp.26481] [PMID]
12. György B, Szabó TG, Pásztói M, Pál Z, Misják P, Aradi B, et al. Membrane vesicles, current state-of-the-art: emerging role of extracellular vesicles. Cell Mol Life Sci. 2011; 68(16) : 2667-88. [DOI:10.1007/s00018-011-0689-3] [PMID] [PMCID]
13. Doyle LM, Wang MZ. Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells. 2019;8(7): 727. [DOI:10.3390/cells8070727] [PMID]
14. Zou X, Lei Q, Luo X, Yin J, chen S, Hao C, et al. Advances in biological functions and applications of apoptotic vesicles. Cell Commun Signal. 2023; 21(1): 260. [DOI:10.1186/s12964-023-01251-9] [PMID] [PMCID]
15. Welsh JA, Goberdhan DC, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, et al. Minimal information for studies of extracellular vesicles (MISEV2023): From basic to advanced approaches. J extracell vesicles. 2024; 13(2): e12404. [DOI:10.1002/jev2.12451] [PMID]
16. Du S, Guan Y, Xie A, Yan Z, Gao S, Li W, et al. Extracellular vesicles: a rising star for therapeutics and drug delivery. J Nanobiotechnology. 2023; 21(1): 231. [DOI:10.1186/s12951-023-01973-5] [PMID] [PMCID]
17. Chen T, Chen D, Su W, Liang J, Liu X, Cai M. Extracellular vesicles as vital players in drug delivery: a focus on clinical disease treatment. Fron Bioeng Biotechnol. 2025; 13: 1600227. [DOI:10.3389/fbioe.2025.1600227] [PMID] [PMCID]
18. Dang XTT, Kavishka JM, Zhang DX, Pirisinu M, Le MT. Extracellular vesicles as an efficient and versatile system for drug delivery. Cells. 2020; 9(10): 2191. [DOI:10.3390/cells9102191] [PMID] [PMCID]
19. Soudi T, Bagheri F, Shojaosadati SA, Rezaei M, Motamedian E. Modified exosomes for targeted delivery of doxorubicin and carvedilol to mitochondria in breast cancer cells. Sci Rep. 2025; 15(1): 38386. [DOI:10.1038/s41598-025-22156-2] [PMID] [PMCID]
20. Li H, Xu W, Li F, Zeng R, Zhang X, Wang X, et al. Amplification of anticancer efficacy by co-delivery of doxorubicin and lonidamine with extracellular vesicles. Drug Deliv. 2022; 29(1): 192-202. [DOI:10.1080/10717544.2021.2023697] [PMID] [PMCID]
21. Torabi S, Yekzaman E, Taherkhani S, Talachi N, Khoshravesh R, Khosravi A, et al. Immune cell-based therapies for solid tumors, current challenges and therapeutic advances. Cell Commu Signal. 2025; 24(1): 73. [DOI:10.1186/s12964-025-02632-y] [PMID] [PMCID]
22. Seydi H, Nouri K, Shokouhian B, Piryaei A, Hassan M, Cordani M, et al. MiR-29a-laden extracellular vesicles efficiently induced apoptosis through autophagy blockage in HCC cells. Eur J Pharm Biopharm. 2024; 203: 114470. [DOI:10.1016/j.ejpb.2024.114470] [PMID]
23. Salehi M, Negahdari B, Hashemi M, Seydi H, Salarinejad S, Piryaei A, et al. Milk-derived extracellular vesicles enhanced Sorafenib's therapeutic response on hepatocellular carcinoma cells. Journal of Drug Delivery Science and Technology. 2026; 117: 108005. [DOI:10.1016/j.jddst.2026.108005]
24. Johnson J, Wu YW, Blyth C, Lichtfuss G, Goubran H, Burnouf T. Prospective Therapeutic Applications of Platelet Extracellular Vesicles. Trends Biotechnol. 2021; 39(6): 598-612. [DOI:10.1016/j.tibtech.2020.10.004] [PMID]
25. Dai Z, Zhao T, Song N, Pan K, Yang Y, Zhu X, et al. Platelets and platelet extracellular vesicles in drug delivery therapy: A review of the current status and future prospects. Front Pharmacol. 2022; 13: 1026386. [DOI:10.3389/fphar.2022.1026386] [PMID] [PMCID]
26. Yao C, Wang C. Platelet-derived extracellular vesicles for drug delivery. Biomaterials Science. 2023; 11(17): 5758-68. [DOI:10.1039/D3BM00893B] [PMID]
27. Chaudhary PK, Kim S, Kim S. Shedding light on the cell biology of platelet-derived extracellular vesicles and their biomedical applications. Life. 2023; 13(6): 1403. [DOI:10.3390/life13061403] [PMID] [PMCID]
28. Burnouf T, Goubran HA, Chou M-L, Devos D, Radosevic M. Platelet microparticles: detection and assessment of their paradoxical functional roles in disease and regenerative medicine. Blood Rev. 2014; 28(4): 155-66. [DOI:10.1016/j.blre.2014.04.002] [PMID]
29. Gasecka A, Nieuwland R, Siljander PRM. Platelet-Derived Extracellular Vesicles. In: Michelson AD, editor. Platelets (Fourth Edition): Academic Press; 2019. p. 401-16. [DOI:10.1016/B978-0-12-813456-6.00022-9]
30. Antich-Rosselló M, Forteza-Genestra MA, Monjo M, Ramis JM. Platelet-Derived Extracellular Vesicles for Regenerative Medicine. Int J Mol Sci. 2021;22(16) :8580. [DOI:10.3390/ijms22168580] [PMID] [PMCID]
31. Vismara M, Manfredi M, Zarà M, Trivigno SMG, Galgano L, Barbieri SS, et al. Proteomic and functional profiling of platelet-derived extracellular vesicles released under physiological or tumor-associated conditions. Cell Death Discov. 2022; 8(1): 467. [DOI:10.1038/s41420-022-01263-3] [PMID] [PMCID]
32. Rui S, Yuan Y, Du C, Song P, Chen Y, Wang H, et al. Comparison and Investigation of Exosomes Derived from Platelet-Rich Plasma Activated by Different Agonists. Cell Transplant. 2021; 30: 9636897211017833. [DOI:10.1177/09636897211017833] [PMID] [PMCID]
33. Théry C, Amigorena S, Raposo G, Clayton A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr Protoc Cell Biol. 2006; Chapter 3: Unit 3.22. [DOI:10.1002/0471143030.cb0322s30] [PMID]
34. Lobb RJ, Becker M, Wen SW, Wong CS, Wiegmans AP, Leimgruber A, et al. Optimized exosome isolation protocol for cell culture supernatant and human plasma. J Extracell Vesicles. 2015; 4: 27031. [DOI:10.3402/jev.v4.27031] [PMID] [PMCID]
35. Konoshenko MY, Lekchnov EA, Vlassov AV, Laktionov PP. Isolation of extracellular vesicles: general methodologies and latest trends. BioMed res intl. 2018; 2018(1): 8545347. [DOI:10.1155/2018/8545347] [PMID]
36. Salehi M, Negahdari B, Vosough M, Shekari F. Treatment of milk with various chemicals differentially affects the physicochemical and functional characteristics of extracellular vesicles. Food Bioscience. 2024; 58: 103570. [DOI:10.1016/j.fbio.2023.103570]
37. Simonsen JB. What Are We Looking At? Extracellular Vesicles, Lipoproteins, or Both? Circ Res. 2017; 121(8): 920-2. [DOI:10.1161/CIRCRESAHA.117.311767] [PMID]
38. Karimi N, Cvjetkovic A, Jang SC, Crescitelli R, Hosseinpour Feizi MA, Nieuwland R, et al. Detailed analysis of the plasma extracellular vesicle proteome after separation from lipoproteins. Cell Mol Life Sci. 2018; 75(15): 2873-86. [DOI:10.1007/s00018-018-2773-4] [PMID] [PMCID]
39. Salehi M, Zarei-Behjani Z, Shafiee A, Agrawal AK. Milk-Derived Extracellular Vesicles: Unlocking Their Potential in Human Health and Disease Treatment. In: Sheykhhasan M, Yang P, Samadi P, Manoochehri H, editors. Extracellular Vesicles: From the Laboratory to the Clinic. Cham: Springer Nature Switzerland. 2026; p: 197-222. [DOI:10.1007/978-3-032-23810-8_6] [PMID] [PMCID]
40. Meliciano A, Salvador D, Mendonça P, Louro AF, Serra M. Clinically Expired Platelet Concentrates as a Source of Extracellular Vesicles for Targeted Anti-Cancer Drug Delivery. Pharmaceutics. 2023; 15(3): 953. [DOI:10.3390/pharmaceutics15030953] [PMID] [PMCID]
41. Aatonen MT, Ohman T, Nyman TA, Laitinen S, Grönholm M, Siljander PR. Isolation and characterization of platelet-derived extracellular vesicles. J Extracell Vesicles. 2014; 3. [DOI:10.3402/jev.v3.24692] [PMID] [PMCID]
42. Li P, Kaslan M, Lee SH, Yao J, Gao Z. Progress in Exosome Isolation Techniques. Theranostics. 2017; 7(3): 789-804. [DOI:10.7150/thno.18133] [PMID] [PMCID]
43. de Menezes-Neto A, Sáez MJ, Lozano-Ramos I, Segui-Barber J, Martin-Jaular L, Ullate JM, et al. Size-exclusion chromatography as a stand-alone methodology identifies novel markers in mass spectrometry analyses of plasma-derived vesicles from healthy individuals. J Extracell Vesicles. 2015; 4: 27378. [DOI:10.3402/jev.v4.27378] [PMID] [PMCID]
44. Böing AN, van der Pol E, Grootemaat AE, Coumans FA, Sturk A, Nieuwland R. Single-step isolation of extracellular vesicles by size-exclusion chromatography. J Extracell Vesicles. 2014; 3. [DOI:10.3402/jev.v3.23430] [PMID] [PMCID]
45. Salehi M, Negahdari B, Mehryab F, Shekari F. Milk-derived extracellular vesicles: biomedical applications, current challenges, and future perspectives. J Agric Food Chem. 2024; 72(15): 8304-31. [DOI:10.1021/acs.jafc.3c07899] [PMID]
46. Baranyai T, Herczeg K, Onódi Z, Voszka I, Módos K, Marton N, et al. Isolation of Exosomes from Blood Plasma: Qualitative and Quantitative Comparison of Ultracentrifugation and Size Exclusion Chromatography Methods. PLoS One. 2015; 10(12): e0145686. [DOI:10.1371/journal.pone.0145686] [PMID] [PMCID]
47. Théry C, Witwer KW, Aikawa E, Alcaraz MJ, Anderson JD, Andriantsitohaina R, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018; 7(1): 1535750. [DOI:10.1080/20013078.2018.1535750] [PMID]
48. Gardiner C, Ferreira YJ, Dragovic RA, Redman CW, Sargent IL. Extracellular vesicle sizing and enumeration by nanoparticle tracking analysis. J Extracell Vesicles. 2013; 2. [DOI:10.3402/jev.v2i0.19671] [PMID] [PMCID]
49. Kowal J, Arras G, Colombo M, Jouve M, Morath JP, Primdal-Bengtson B, et al. Proteomic comparison defines novel markers to characterize heterogeneous populations of extracellular vesicle subtypes. Proc Natl Acad Sci U S A. 2016; 113(8): E968 - 77. [DOI:10.1073/pnas.1521230113] [PMID]
50. Ha D, Yang N, Nadithe V. Exosomes as therapeutic drug carriers and delivery vehicles across biological membranes: current perspectives and future challenges. Acta Pharm Sin B. 2016; 6(4): 287-96. [DOI:10.1016/j.apsb.2016.02.001] [PMID]
51. Andaloussi S E, Mäger I, Breakefield XO, Wood MJA. Extracellular vesicles: biology and emerging therapeutic opportunities. Nat Rev Drug Discov. 2013; 12(5): 347-57. [DOI:10.1038/nrd3978] [PMID]
52. Brezgin S, Danilik O, Yudaeva A, Kachanov A, Kostyusheva A, Karandashov I, et al. Basic Guide for Approaching Drug Delivery with Extracellular Vesicles. Int J Mol Sciences. 2024; 25(19): 10401. [DOI:10.3390/ijms251910401] [PMID] [PMCID]
53. Mehryab F, Rabbani S, Shahhosseini S, Shekari F, Fatahi Y, Baharvand H, et al. Exosomes as a next-generation drug delivery system: An update on drug loading approaches, characterization, and clinical application challenges. Acta Biomater. 2020; 113: 42-62. [DOI:10.1016/j.actbio.2020.06.036] [PMID]
54. Zhang K, Fang J. Extracellular vesicles in drug delivery: from quality assurance to therapeutic application. Int J Nanomedicine. 2026; 21 : 579695. [DOI:10.2147/IJN.S579695] [PMID] [PMCID]
55. Fuhrmann G, Serio A , Mazo M, Nair R, Stevens MM. Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins. J Control Release. 2015; 205: 35-44. [DOI:10.1016/j.jconrel.2014.11.029] [PMID]
56. Alvarez-Erviti L, Seow Y, Yin H, Betts C, Lakhal S, Wood MJA. Delivery of siRNA to the mouse brain by systemic injection of targeted exosomes. Nat Biotechnol. 2011; 29(4): 341-5. [DOI:10.1038/nbt.1807] [PMID]
57. Lamichhane TN, Jeyaram A, Patel DB, Parajuli B, Livingston NK, Arumugasaamy N, et al. Oncogene Knockdown via Active Loading of Small RNAs into Extracellular Vesicles by Sonication. Cell Mol Bioeng. 2016; 9(3): 315-24. [DOI:10.1007/s12195-016-0457-4] [PMID] [PMCID]
58. Wahlgren J, De LKT, Brisslert M, Vaziri Sani F, Telemo E, Sunnerhagen P, et al. Plasma exosomes can deliver exogenous short interfering RNA to monocytes and lymphocytes. Nucleic Acids Res. 2012; 40(17): e130. [DOI:10.1093/nar/gks463] [PMID] [PMCID]
59. Kooijmans SAA, Stremersch S, Braeckmans K, de Smedt SC, Hendrix A, Wood MJA, et al. Electroporation-induced siRNA precipitation obscures the efficiency of siRNA loading into extracellular vesicles. J Control Release. 2013; 172(1): 229-38. [DOI:10.1016/j.jconrel.2013.08.014] [PMID]
60. Haney MJ, Klyachko NL, Zhao Y, Gupta R, Plotnikova EG, He Z, et al. Exosomes as drug delivery vehicles for Parkinson's disease therapy. J Control Release. 2015; 207: 18-30. [DOI:10.1016/j.jconrel.2015.03.033] [PMID]
61. Kim MS, Haney MJ, Zhao Y, Yuan D, Deygen I, Klyachko NL, et al. Engineering macrophage-derived exosomes for targeted paclitaxel delivery to pulmonary metastases: in vitro and in vivo evaluations. Nanomedicine. 2018; 14(1): 195-204. [DOI:10.1016/j.nano.2017.09.011] [PMID] [PMCID]
62. Zhuang T, Wang S, Yu X, He X, Guo H, Ou C. Current status and future perspectives of platelet-derived extracellular vesicles in cancer diagnosis and treatment. Biomark Res. 2024; 12(1): 88. [DOI:10.1186/s40364-024-00639-0] [PMID] [PMCID]
63. Wu YW, Lee DY, Lu YL, Delila L, Nebie O, Barro L, et al. Platelet extracellular vesicles are efficient delivery vehicles of doxorubicin, an anti-cancer drug: preparation and in vitro characterization. Platelets. 2023; 34(1): 2237134. [DOI:10.1080/09537104.2023.2237134] [PMID]
64. Lucas A, Lam D, Cabrales P. Doxorubicin-loaded red blood cells reduced cardiac toxicity and preserved anticancer activity. Drug Deliv. 2019; 26(1) :433-42. [DOI:10.1080/10717544.2019.1591544] [PMID] [PMCID]
65. Schindler C, Collinson A, Matthews C, Pointon A, Jenkinson L, Minter RR, et al. Exosomal delivery of doxorubicin enables rapid cell entry and enhanced in vitro potency. PLoS One. 2019; 14(3): e0214545. [DOI:10.1371/journal.pone.0214545] [PMID] [PMCID]
66. Zhao J, Ye H, Lu Q, Wang K, Chen X, Song J, et al. Inhibition of post-surgery tumour recurrence via a sprayable chemo-immunotherapy gel releasing PD-L1 antibody and platelet-derived small EVs. J Nanobiotechnology. 2022; 20(1): 62. [DOI:10.1186/s12951-022-01270-7] [PMID]
67. Haddad R, Alrabadi N, Altaani B, Li T. Paclitaxel Drug Delivery Systems: Focus on Nanocrystals' Surface Modifications. Polymers [Internet]. 2022; 14(4): 658. [DOI:10.3390/polym14040658] [PMID] [PMCID]
68. Ning S, Zhang X, Suo M, Lyu M, Pan Y, Jiang Y, et al. Platelet-derived exosomes hybrid liposomes facilitate uninterrupted singlet oxygen generation to enhance breast cancer immunotherapy. Cell Reports Physical Science. 2023; 4(7): 101505. [DOI:10.1016/j.xcrp.2023.101505]
69. Guo J, Cui B, Zheng J, Yu C, Zheng X, Yi L, et al. Platelet-derived microparticles and their cargos: The past, present and future. Asian J Pharm Sci. 2024; 19(2): 100907. [DOI:10.1016/j.ajps.2024.100907] [PMID] [PMCID]
70. Weiss L, Macleod H, Maguire PB. Platelet-derived extracellular vesicles in cardiovascular disease and treatment - from maintaining homeostasis to targeted drug delivery. Curr Opin Hematol. 2025; 32(1): 4-13. [DOI:10.1097/MOH.0000000000000845] [PMID] [PMCID]
71. Livkisa D, Chang TH, Burnouf T, Czosseck A, Le NTN, Shamrin G, et al. Extracellular vesicles purified from serum-converted human platelet lysates offer strong protection after cardiac ischaemia/reperfusion injury. Biomaterials. 2024; 306: 122502. [DOI:10.1016/j.biomaterials.2024.122502] [PMID] [PMCID]
72. Pawlowski CL, Li W, Sun M, Ravichandran K, Hickman D, Kos C, et al. Platelet microparticle-inspired clot-responsive nanomedicine for targeted fibrinolysis. Biomaterials. 2017; 128: 94-108. [DOI:10.1016/j.biomaterials.2017.03.012] [PMID] [PMCID]
73. Formica ML, Pernochi Scerbo JM, Awde Alfonso HG, Palmieri PT, Ribotta J, Palma SD. Nanotechnological approaches to improve corticosteroids ocular therapy. Methods. 2025; 234: 152-77. [DOI:10.1016/j.ymeth.2024.12.008] [PMID]
74. Ozbakir B, Crielaard BJ, Metselaar JM, Storm G, Lammers T. Liposomal corticosteroids for the treatment of inflammatory disorders and cancer. Journal of Controlled Release. 2014; 190: 624-36. [DOI:10.1016/j.jconrel.2014.05.039] [PMID]
75. Ma Q, Fan Q, Xu J, Bai J, Han X, Dong Z, et al. Calming Cytokine Storm in Pneumonia by Targeted Delivery of TPCA-1 Using Platelet-Derived Extracellular Vesicles. Matter. 2020; 3(1): 287-301. [DOI:10.1016/j.matt.2020.05.017] [PMID] [PMCID]
76. Ma Q, Bai J, Xu J, Dai H, Fan Q, Fei Z, et al. Reshaping the Inflammatory Environment in Rheumatoid Arthritis Joints by Targeting Delivery of Berberine with Platelet‐Derived Extracellular Vesicles. Advanced NanoBiomed Research. 2021; 1 (11). [DOI:10.1002/anbr.202100115]
77. Soleymani S, Yari F, Bolhassani A, Bakhshandeh H. Platelet microparticles: An effective delivery system for anti-viral drugs. Journal of Drug Delivery Science and Technology. 2019; 51(2). [DOI:10.1016/j.jddst.2019.03.009]
78. Bangar SP, Chaudhary V, Sharma N, Bansal V, Ozogul F, Lorenzo JM. Kaempferol: A flavonoid with wider biological activities and its applications. Crit Rev Food Sci Nutr. 2023; 63(28): 9580-604. [DOI:10.1080/10408398.2022.2067121] [PMID]
79. Liu GS , Chen HA, Chang CY, Chen YJ, Wu YY, Widhibrata A, et al. Platelet-derived extracellular vesicle drug delivery system loaded with kaempferol for treating corneal neovascularization. Biomaterials. 2025; 319: 123205. [DOI:10.1016/j.biomaterials.2025.123205] [PMID]
80. Shams SF, Mohammadipour M, Deyhim MR. Platelet-derived exosomes as the nano-carrier for miR-150 to modulate gene expression and cell cycle in the M07-e cell line. Journal of Drug Delivery Science and Technology. 2023; 86: 104644. [DOI:10.1016/j.jddst.2023.104644]
81. Kubaev A, Faez Sead F, Pirouzbakht M, Nazari M, Riyahi H, Sargazi Aval O, et al. Platelet-derived extracellular vesicles: emerging players in hemostasis and thrombosis. J Liposome Res. 2025; 35(3): 334-44. [DOI:10.1080/08982104.2025.2495261] [PMID]
82. Dyer MR, Alexander W, Hassoune A, Chen Q, Brzoska T, Alvikas J, et al. Platelet‐derived extracellular vesicles released after trauma promote hemostasis and contribute to DVT in mice. J Thromb Haemost. 2019; 17(10): 1733-45. [DOI:10.1111/jth.14563] [PMID] [PMCID]
83. Muttiah B, Ng SL, Lokanathan Y, Ng MH, Law JX. Beyond Blood Clotting: The Many Roles of Platelet-Derived Extracellular Vesicles. Biomedicines. 2024; 12(8): 1850. [DOI:10.3390/biomedicines12081850] [PMID] [PMCID]
84. Fan Z, Gan Y, Hu Y. The potential utilization of platelet-derived extracellular vesicles in clinical treatment. Platelets. 2024; 35(1): 2397592. [DOI:10.1080/09537104.2024.2397592] [PMID]
85. Eustes AS, Dayal S. The Role of Platelet-Derived Extracellular Vesicles in Immune-Mediated Thrombosis. Int J Mol Sci. 2022; 23(14): 7837. [DOI:10.3390/ijms23147837] [PMID] [PMCID]
86. Noren Hooten N, Byappanahalli AM, Vannoy M, Omoniyi V, Evans MK. Influences of age, race, and sex on extracellular vesicle characteristics. Theranostics. 2022; 12(9): 4459-76. [DOI:10.7150/thno.72676] [PMID] [PMCID]
87. Orrù V, Virdis F, Marongiu M, Serra V, Schlessinger D, Devoto M, et al. Effect of Genetic Factors, Age and Sex on Levels of Circulating Extracellular Vesicles and Platelets. Int J Mol Sci . 2023; 24(8): 7183. [DOI:10.3390/ijms24087183] [PMID] [PMCID]
88. Lou C, Cai X. The emerging roles of platelet-derived extracellular vesicles in disease. Ann Med. 2025; 57(1): 2499029. [DOI:10.1080/07853890.2025.2499029] [PMID] [PMCID]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
